L&C Bio (290650.KQ) Earnings Analysis

L&C Bio (290650.KQ) next reports earnings on 2026-08-19, consensus EPS 140.94 KRW. Trailing P/E -11.00.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 290650.KQ next report earnings?

Next earnings date2026-08-19
Consensus EPS estimate140.94 KRW
Revenue estimate39.70B

290650.KQ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-11104.64 KRWn/an/an/a
2026-02-27-2,945.42 KRWn/an/an/a
2025-11-14-2,289 KRWn/an/an/a
2025-08-14-605.33 KRWn/an/an/a
2025-05-15-18.85 KRWn/an/an/a
2025-02-246,431.2 KRWn/an/an/a
2024-11-14-228 KRWn/an/an/a
2024-08-1446.95 KRWn/an/an/a

290650.KQ valuation and analyst view

Trailing P/E-11.00
Trailing EPS-5,193.66954 KRW
Price / book8.09
Dividend yield0.08%
Market cap1501.50B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is L&C Bio (290650.KQ)'s next earnings date?

L&C Bio is next scheduled to report on 2026-08-19, with a consensus EPS estimate of 140.94 KRW and revenue estimate of 39.70B.

Did 290650.KQ beat earnings last quarter?

Consensus estimate data was not available for 290650.KQ's 2026-05-11 report.

What is 290650.KQ's current P/E ratio and EPS?

290650.KQ trades at a trailing P/E of -11.00 on trailing EPS of -5193.669536143884 KRW.

What do analysts rate 290650.KQ?

290650.KQ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.